RADNOR, PA — Clinical-stage biopharmaceutical company NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has announced plans to hold its 2023 Annual Meeting of Stockholders on December 19, 2023. The meeting, scheduled for 11:00 a.m. Eastern Time, will take place in a virtual-only format.
The management team at NRx Pharmaceuticals is set to discuss several key items detailed in the Proxy Statement. One significant point on the agenda is the proposed election of Janet Rehnquist to the Company’s Board of Directors. Rehnquist is a widely respected attorney boasting over 25 years of experience in highly regulated industries, with a particular focus on healthcare.
In addition to Rehnquist’s potential appointment, the management will also shed light on the planned spinoff of Hope Therapeutics, Inc., a company focused on IV Ketamine. This promising venture is expected to be initially owned by NRx Pharmaceuticals and individual NRx shareholders through a dividend or a similar mechanism, along with new investors.
NRx Pharmaceuticals encourages all stockholders and interested parties to attend the virtual meeting. This gathering provides a unique opportunity to gain insights into the company’s strategic vision, including its expansion into new areas of therapy and the strengthening of its board with top-tier talent.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.